Abstract
Purpose. For the individual optimization of drug therapy with sulfasalazine (SASP), we studied the influence of the N-acetyltransferase 2 (NAT2) genotype on the pharmacokinetics, efficacy, and incidence of adverse reactions of SASP in patients.
Methods. Ninety-six rheumatoid arthritis (RA) patients were treated or had been treated with 0.5 and/or 1.0 g/day of SASP. The wild-type allele (NAT2*4) and three variant alleles (NAT2*5B, *6A, and *7B) of NAT2 were determined by the polymerase chain reaction-restriction fragment length polymorphism method. Plasma concentrations of SASP and its two metabolites, sulfapyridine (SP) and N-acetylsulfapyridine (AcSP), were estimated by HPLC. Therapeutic efficacy and incidence of adverse reactions were also monitored as recommended by the American College of Rheumatology.
Results. Patients were classified into three groups by NAT2 genotyping: Rapid Type (homozygote for NAT2*4), Intermediate Type (heterozygote for NAT2*4 and variant alleles), and Slow Type (homozygote for variant alleles). There was no clear difference in the genotype frequencies between RA patients and healthy subjects. NAT2 genotypes significantly affected both the plasma concentration ratios of SP to AcSP (SP/AcSP) and the efficacy of SASP (p < 0.05). Adverse reactions to SASP were found in 26 (27.1%) out of 96 patients, and there was no difference among the three genotype groups.
Conclusions. NAT2 gene polymorphism is related to the plasma SP/AcSP ratio and the efficacy of SASP.
Similar content being viewed by others
references
D. M. van der Heijde, P. L. van Riel, I. H. Nuver-Zwart, F. W. Gribnau, and L. B. van de Putte. Effect of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036-1038 (1989).
U. Klotz. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet. 10:285-302 (1985).
K. M. Das and R. Dubin. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet. 1:406-425 (1976).
G. Carlin, R. Djursater, and G. Smedegard. Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes. Pharmacol. Toxicol. 65:121-127 (1989).
M. Fujiwara, K. Mitsui, and I. Yamamoto. Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. Jpn. J. Pharmacol. 54:121-131 (1990).
K. M. Das, M. A. Eastwood, J. P. A. McManus, and W. Sircus. The metabolism of salicylazosulphapyridine in ulcerative colitis. Gut 14:631-641 (1973).
A. K. Azad Khan, D. T. Howes, J. Piris, and S. C. Truelove. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 21:232-240 (1980).
K. M. Das, M. A. Eastwood, J. P. A. McManus, and W. Sircus. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N. Engl. J. Med. 289:491-495 (1973).
H. Schroder and D. A. P. Evans. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 13:278-284 (1972).
D. A. P. Evans. N-Acetyltransferase. Pharmacol. Ther. 42:157-234 (1989).
C. J. Laversuch, D. A. Collins, P. J. Charles, and B. E. Bourke. Sulphasalazine autoimmune abnormalities in patients with rheumatic disease. Br. J. Rheumatol. 34:435-439 (1995).
G. D. Kitas, M. Farr, L. Waterhouse, and P. A. Bacon. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand. J. Rheumatol. 21:220-225 (1992).
T. Pullar, J. A. Hunter, and H. A. Capell. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann. Rheum. Dis. 44:831-837 (1985).
D. E. Bax, M. S. Greaves, and R. S. Amos. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br. J. Rheumatol. 25:282-284 (1986).
C. P. Rains, S. Noble, and D. Faulds. Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50:137-156 (1995).
A. J. Taggart, B. J. McDermott, and S. D. Roberts. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. Clin. Pharmacokinet. 23:311-320 (1992).
S. Ohsako and T. Deguchi. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J. Biol. Chem. 265:4630-4634 (1990).
M. Abe, T. Deguchi, and T. Suzuki. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem. Biophys. Res. Commun. 191:811-816 (1993).
K. Okumura, T. Kita, S. Chikazawa, F. Komada, S. Iwakawa, and Y. Tanigawara. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin. Pharmacol. Ther. 61:509-517 (1997).
T. Kita, Y. Tanigawara, S. Chikazawa, H. Hatanaka, T. Sakaeda, F. Komada, S. Iwakawa, and K. Okumura. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Bio. Pharm. Bull. 24:544-549 (2001).
Y. Tanigawara, T. Kita, N. Aoyama, M. Gobara, F. Komada, T. Sakai, M. Kasuga, H. Hatanaka, T. Sakaeda, and K. Okumura. N-Acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol. Pharm. Bull. 25:1058-1062 (2002).
T. Kita, T. Sakaeda, S. Adachi, T. Sakai, N. Aoyama, H. Hatanaka, M. Kasuga, and K. Okumura. N-Acetyltansferase 2 genotype correlates with sulfasarazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol. Pharm. Bull. 24:1176-1180 (2001).
D. T. Felson, J. J. Anderson, M. Boers, C. Bombardier, D. Furst, C. Goldsmith, L. M. Katz, R. Jr. Lightfoot, H. Paulus, and V. Strand. American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:727-735 (1995).
T. Deguchi, M. Mashimo, and T. Suzuki. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 265:12757-12760 (1990).
M. Mashimo, T. Suzuki, M. Abe, and T. Deguchi. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum. Genet. 90:139-143 (1992).
C. Maslinski and A. Fogel. Catabolism of histamine. In B. Uvans (ed.), Handbook of Experimental Pharmacology: Histamine and Histamine Antagonists, Berlin: Springer-Verlag, 1991, pp. 165-189.
Y. Endo. Elevation of histamine levels in rat and mouse tissue by deacetylation of administered N-acetylhistamine. Eur. J. Pharmacol. 60:299-305 (1979).
H. Tabor, A. H. Mehler, and E. R. Stadtman. The enzymatic acetylation of amines. J. Biol. Chem. 204:127-138 (1953).
A. Pawlik, L. Ostanek, I. Brzosko, B. Gawroska-Szklarz, M. Brzosko, and E. Dabrowska-Zamojcin. Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 72:319-325 (2002).
E. Uchida, K. Kai, S. Kobayashi, K. Oguchi, Y. Miyazaki, and H. Yasuhara. A study of pharmacokinetics and safety of salazosulfapyridine enteric coated tablet (PJ-306) in healthy Japanese subjects. Jpn. J. Pharmacol. Ther. 21:377-389 (1990).
T. Pullar. Adverse effects of sulphasalazine. Adverse Drug React. Toxicol. Rev. 11:93-109 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kumagai, S., Komada, F., Kita, T. et al. N-Acetyltransferase 2 Genotype-Related Efficacy of Sulfasalazine in Patients with Rheumatoid Arthritis. Pharm Res 21, 324–329 (2004). https://doi.org/10.1023/B:PHAM.0000016246.84974.ec
Issue Date:
DOI: https://doi.org/10.1023/B:PHAM.0000016246.84974.ec